Personalised medicine company Spesana and Imidex, developer of computer-aided detection technology, have announced a strategic partnership to explore AI's impact on lung cancer detection. The collaboration will combine Imidex's VisiRad XR detection algorithm and Spesana's medical data platform to study the detection rates of lung nodules and masses in existing chest x-rays.

The clinical trial aims to quantify how many additional lung masses can be identified, identify at-risk patients for clinical trials, and evaluate the use of liquid biopsies resulting from nodule detection. Carla Balch, CEO of Spesana, envisions early lung cancer detection leading to earlier treatment and better patient outcomes.

Wes Bolsen, CEO of Imidex, highlighted that their FDA-cleared algorithm will improve the screening of potential lung cancer patients. The collaboration aims to equip healthcare providers and pharmaceutical companies with tools to detect lung nodules earlier, optimising healthcare resources and improving patient outcomes.